Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M) PARIS, France, July 2, 2026 – 8:00 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness the
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares Upsized offering increased from the previously announced $600M to $800M at $125.00 per ADS, priced at a 2.39% premium to the three-day VWAP Expected gross proceeds of approximately
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that harness
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“ Abivax ” or the “ Company ”), a clinical-stage biotechnology company focused on developing therapeutics that
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative
Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3%
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat (“ITT”) analysis from Study 108 supports strong
Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Cash runway remains into Q4 2027, supporting continued funding of clinical programs and pre-commercial planning activities Royalty overhang materially reduced, enhancing financial
Abivax to Present Data on Obefazimod at Digestive Disease Week ® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST –
PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX)
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn’s and Colitis Organization’s (ECCO) 21 st Annual Congress illustrate the depth and breadth